MAP2K7 and neoplasm: Therefore, the anti-tumor effects of these BRAF inhibitors are enhanced by co-administration of MEK inhibitors [9,10,11], and combined therapy with a BRAF inhibitor and MEK inhibitor is recommended as one of the first-line therapies for advanced BRAF-V600-mutated melanoma.